# OnCo record guardant360-liquid-cdx (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/guardant360-liquid-cdx/>
  a schema:MedicalTest ;
  onco:kind "drug" ;
  schema:identifier "guardant360-liquid-cdx" ;
  schema:name "Guardant360 Liquid CDx"@en ;
  schema:description "A blood test from Guardant Health that reads tumour DNA in the bloodstream to find out whether certain targeted drugs for lung, breast or bowel cancer may work."@en ;
  schema:url <https://onco.cc/drugs/guardant360-liquid-cdx/> ;
  schema:dateModified "2026-11-17"^^xsd:date ;
  schema:citation <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P250027>, <https://api.fda.gov/device/pma.json?search=pma_number:P250027>, <https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-fda-authorized-companion-diagnostic-devices-in-vitro-and-imaging-tools> ;
  onco:status "approved" ;
  onco:tag "test" ;
  onco:modality "Liquid biopsy companion diagnostic test (NGS, cfDNA)" ;
  schema:alternateName "Guardant360 Liquid CDx" ;
  onco:approval "US 2026: Companion diagnostic (plasma) for osimertinib, amivantamab, sotorasib and trastuzumab deruxtecan in NSCLC, elacestrant and imlunestrant in breast cancer, and encorafenib in colorectal cancer; also tumour mutation profiling in solid tumours" ;
  onco:related <https://onco.cc/drugs/guardant360-cdx/>, <https://onco.cc/biomarkers/egfr-exon-19-deletion/>, <https://onco.cc/biomarkers/egfr-l858r/>, <https://onco.cc/biomarkers/egfr-t790m/>, <https://onco.cc/biomarkers/egfr-exon-20-insertion/>, <https://onco.cc/biomarkers/kras-g12c/>, <https://onco.cc/biomarkers/her2-mutation/>, <https://onco.cc/biomarkers/braf-v600e/>, <https://onco.cc/biomarkers/esr1-mutation-ctdna/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/companion-diagnostic/>, <https://onco.cc/technologies/cgp/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/estrogen-receptor/>, <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/elacestrant/>, <https://onco.cc/drugs/imlunestrant/>, <https://onco.cc/drugs/encorafenib/> ;
  onco:companies <https://onco.cc/companies/guardant-health/> ;
  onco:terms <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/companion-diagnostic-term/> .
